Get to know our clinical trials

Clinical trial of CC-90009, a new Cereblon E3 Ligase modulator drug, in subjects with Acute Myeloid Leukemia

THE MAIN OBJECTIVE OF THIS STUDY IS TO ANALYZE THE SAFETY (ANY GOOD OR BAD EFFECTS) OF THE NEW EXPERIMENTAL DRUG, CC-90009 (STUDY TREATMENT). IT IS ALSO TO DETERMINE IF CC-90009 CAN CONTROL YOUR DISEASE AND TO EXPLORE HOW LONG THIS DRUG STAYS IN YOUR BODY.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE I, OPEN-LABEL, DOSE-FINDING TRIAL OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATOR DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR RELAPSED OR REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROMES
  • Code EudraCT: 2017-001535-39
  • Protocol number: CC-90009-AML-001
  • Promoter: Celgene Corporation
  • Molecule/Drug: CC-90009
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.